论文部分内容阅读
目的研究DCD(Dermcidin)与原发性肝细胞癌(HCC)的相关性,探讨DCD作为原发性肝癌生物标记物的可能性,提高HCC早期检出率。方法分别收集广州市中医医院2013年1月至2014年12月46例HCC患者,33例乙肝肝硬化患者,25例健康对照者的临床资料及血清。分别采用ELISA和电化学发光免疫分析法方法对样品进行检测DCD和AFP,结果采用SPSS 19方法进行相关分析。结果 HCC组血清中DCD的含量(中位数26.03 ng/m L,IQR:20.12~34.56 ng/m L)显著高于健康对照组(中位数18.12 ng/m L,IQR:11.22~22.35 ng/m L,P<0.001),差异有统计学意义。DCD在肝癌转移组(中位数33.34 ng/m L,IQR:22.45~44.20 ng/m L);未转移组(中位数22.90 ng/m L,IQR:18.13~30.88 ng/m L)。结论DCD在HCC患者血清中浓度高于乙肝肝硬化组及正常对照组,同时肝癌发生转移的患者血清中DCD浓度高于未转移组,DCD是一种新原发性肝癌的血清标志物,用于原发性肝癌的早期及是否发生转移的判断。
Objective To study the correlation between Dermcidin and primary hepatocellular carcinoma (HCC) and to explore the possibility of using DCD as a biomarker of primary liver cancer to improve the early detection rate of HCC. Methods The clinical data and serum of 46 HCC patients, 33 hepatitis B cirrhosis patients and 25 healthy controls from January 2013 to December 2014 in Guangzhou Traditional Chinese Medicine Hospital were collected. Samples were tested for DCD and AFP by ELISA and electrochemiluminescence immunoassay, and the results were analyzed by SPSS 19. Results The serum levels of DCD in HCC group (median 26.03 ng / m L, IQR: 20.12-34.56 ng / m L) were significantly higher than those in healthy controls (median 18.12 ng / m L, IQR 11.22-22.35 ng / m L, P <0.001), the difference was statistically significant. DCD was significantly higher in patients with liver cancer (median 33.34 ng / m L, IQR: 22.45 to 44.20 ng / m L) and no metastasis (median 22.90 ng / m L, IQR: 18.13-30.88 ng / m L). Conclusions The concentration of DCD in serum of HCC patients is higher than that in hepatitis B cirrhosis patients and normal controls. DCD concentration in serum of patients with HCC metastasis is higher than that in non-metastatic patients. DCD is a serum marker of new primary liver cancer. In the early diagnosis of primary liver cancer and whether the transfer of judgment.